Nimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alone. “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor ...

Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical company New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a ...

Although cannabinoid CB1 receptors are downregulated in the brain with chronic cannabis use, recovery of deficits is observed after just 4 weeks of abstinence. News & Perspective Drugs & Diseases ...